East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Certolizumab pegol
Cimzia
Routinely available
NICE (TA445 (SMC 973/14))
29/03/2023

Indication

In combination with methotrexate, for the treatment of active psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug (DMARD) therapy has been inadequate. Certolizumab pegol can be given as monotherapy in case of intolerance to methotrexate or when continued ...

In combination with methotrexate, for the treatment of active psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug (DMARD) therapy has been inadequate. Certolizumab pegol can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Routinely available in line with national guidance

Formulation

200mg/mL solution for injection in pre-filled syringe

Comments

March 2023- ERF status update included in the pathway Treatment of psoriatic arthritis with biologics in pregnancy.

Link to Advice

TA445 (SMC 973/14)

Advice Published

24/05/2017